31 min
BioSenic developing severe knee osteoarthritis treatment Beyond Biotech - the podcast from Labiotech
-
- Tech News
BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria. The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA). This week...
BioSenic, a Belgian clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, will share data on its late-clinical asset JTA-004 at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria. The post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and efficacious for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis (OA). This week...
31 min